IL-23 Signaling and Its Modulation in Scleroderma (Systemic Sclerosis): Novel Therapy

Project: Research project

Project Details


We will test the hypothesis that IL-23 is a new and important player and potential target in systemic sclerosis (SSc). We hypothesize that IL-23 signaling plays a critical pathogenic role in SSc by driving fibrosis, vasculopathy and/or inflammation. Therefore, we predict that blocking IL-23 will prevent and promote resolution of tissue inflammation and fibrosis in preclinical disease models of scleroderma in the mouse. Antibody blockade of IL-23 might therefore be potential novel treatment in SSc patients demonstrating evidence of activated IL-23 signaling in lesional skin.
Effective start/end date7/11/198/31/20


  • Sun Pharma Global FZE (IS00011264)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.